Recombinant multi-species DLL3 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine DLL3 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
This gene encodes a member of the delta protein ligand family. This family functions as Notch ligands that are characterized by a DSL domain, EGF repeats, and a transmembrane domain. Mutations in this gene cause autosomal recessive spondylocostal dysostosis 1. Two transcript variants encoding distinct isoforms have been identified for this gene. [provided by RefSeq, Jul 2008]
The Alternative Names of target: DLL3,Delta-like protein 3,Dll3,Drosophila Delta homolog 3 (Delta3),SCDO1,pu,pudgy

Target products collectionGo to DLL3 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No. Product Name Species Reactivity
GM-Tg-hg-IP0082-Ag-1/ GM-Tg-hg-IP0082-Ag-2 Human DLL3 protein Human
GM-Tg-rg-IP0082-Ag-1/ GM-Tg-rg-IP0082-Ag-2 Rat DLL3 protein Rat
GM-Tg-mg-IP0082-Ag-1/ GM-Tg-mg-IP0082-Ag-2 Mouse DLL3 protein Mouse
GM-Tg-cynog-IP0082-Ag-1/ GM-Tg-cynog-IP0082-Ag-2 Cynomolgus/Rhesus macaque DLL3 protein Cynomolgus/ Rhesus macaque
GM-Tg-felg-IP0082-Ag-1/ GM-Tg-felg-IP0082-Ag-2 Feline DLL3 protein Feline
GM-Tg-cang-IP0082-Ag-1/ GM-Tg-cang-IP0082-Ag-2 Canine DLL3 protein Canine
GM-Tg-bovg-IP0082-Ag-1/ GM-Tg-bovg-IP0082-Ag-2 Bovine DLL3 protein Bovine
GM-Tg-equg-IP0082-Ag-1/ GM-Tg-equg-IP0082-Ag-2 Equine DLL3 protein Equine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No. GM-Tg-hg-IP0082-Ag-1/ GM-Tg-hg-IP0082-Ag-2; GM-Tg-rg-IP0082-Ag-1/ GM-Tg-rg-IP0082-Ag-2;
GM-Tg-mg-IP0082-Ag-1/ GM-Tg-mg-IP0082-Ag-2; GM-Tg-cynog-IP0082-Ag-1/ GM-Tg-cynog-IP0082-Ag-2;
GM-Tg-felg-IP0082-Ag-1/ GM-Tg-felg-IP0082-Ag-2; GM-Tg-cang-IP0082-Ag-1/ GM-Tg-cang-IP0082-Ag-2;
GM-Tg-bovg-IP0082-Ag-1/ GM-Tg-bovg-IP0082-Ag-2; GM-Tg-equg-IP0082-Ag-1/ GM-Tg-equg-IP0082-Ag-2
Products Name DLL3 protein
Species Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine
Target Name DLL3
Protein Sub-location Introcelluar Protein
Isotypes Recombinant protein
Expression platform Mammalian cell
Bioactivity validation Affintiy&bioactivity validated by ELISA, cell culture validated.
Tag His
Products description Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine DLL3 protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Purity Purity: ≥95% (SDS-PAGE)
Application In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference






    About Gmab

    GDU
    GDU

    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.